Buclizine Hydrochloride

First generation antihistamine, piperazine derivative with moderate sedative and antocolinergic effects. Antivertiginous, antipruritic and antiemetic properties ^{(MK 2019, Mostafa 2011).} Used in the treatment and prevention of travel sickness, as an antivertiginous and antimigraine (associated with several other drugs) and as an appetite stimulant without documented evidence of efficacy ^{(Babu 2011)}. Oral administration once daily. Occasional use for the duration of the trip. 

At the time of last update, we found no published data on its excretion in breast milk.

Product with very few bibliographic references and very old, marketed in few countries. 

The scarcity of known pharmacokinetic data does not allow a good prediction of possible excretion in breast milk. 

The occasional or minimal use of antihistamines, even first generation ones, is considered safe during lactation ^{(So 2010)}, detecting a low frequency of side effects, which are also mild ^{(Ito 1993)}, so the occasional use of Buclizine to prevent motion sickness during a trip can be considered compatible with breastfeeding. 

Buclizine preparations associated with various drugs are not recommended during lactation, nor is there evidence that it is effective in treating vertigo or migraine or other conditions. 

It has an antiprolactin effect that could inhibit lactation in the first weeks after delivery.

Monitor drowsiness and adequate infant feeding if this drug is used during lactation. 

Due to its sedative effect, bed-sharing with the infant is not recommended if taking this medication due to increased risk of suffocation or sudden infant death. ^{(UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006)}